Evaluation of the effectiveness of Hydroxychloroquine and Clarithromycin in dyspnea and caugh caused by COVID-19 in recovery phase

Phase 3

Recruiting

• Conditions: COVID-19.; U07.1; COVID19 ,virus identified

• Registration Number: IRCT20200718048129N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Patients with definitive diagnosis of COVID19 were hospitalized and treated
Patients with COVID19 who still have dyspena and cough two weeks after discharge from the hospital
Patients with COVID19 who continue to have lung involvement on CT SCAN two weeks after discharge

Exclusion Criteria

Patients with comorbidities such as chronic heart or lung disease before COVID19
The need for long-term use of drugs that have an irreversible interaction with the drugs used in the plan.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Dyspnea. Timepoint: Beginning of the study (before the intervention), 14, 30 days after the start of the study. Method of measurement: Medical Research Council(MRC).;Cough. Timepoint: Beginning of the study (before the intervention), 14, 30 days after the start of the study. Method of measurement: visual analogue scale(vas).

Secondary Outcome Measures

Name	Time	Method
ung function. Timepoint: At the beginning of the study (before the intervention) and 30 days later at the end of the study. Method of measurement: six minute walk test(6MW).